Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2002-01-25
- Employees
- 1K
- Market Cap
- -
- Website
- https://www.3s-guojian.com
Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- Drug: Matching placebo
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-06-27
- Target Recruit Count
- 180
- Registration Number
- NCT07042126
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳The Fourth Affiliated Hospital Zhejiang University School of Medicine, Jinhua, Zhejiang, China
🇨🇳Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Nanchang, Zhejiang, China
A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: new formulations of 611Drug: existing formulations of 611
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-06-27
- Target Recruit Count
- 180
- Registration Number
- NCT07042113
- Locations
- 🇨🇳
The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, zhejiangsheng, China
🇨🇳Shanghai General Hospital, Shanghai, China
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-07-03
- Target Recruit Count
- 594
- Registration Number
- NCT07039669
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
🇨🇳Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Target Recruit Count
- 225
- Registration Number
- NCT06680947
Evaluation of 626 in Healthy Adult Subjects
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 50
- Registration Number
- NCT06674525
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, China
A Study to Evaluate 611 in Patients with Chronic Rhinosinusitis with Nasal Polyps
- First Posted Date
- 2024-10-14
- Last Posted Date
- 2024-10-14
- Target Recruit Count
- 240
- Registration Number
- NCT06639295
- Locations
- 🇨🇳
Site 01, Beijing, Beijing, China
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
- Conditions
- Dermatitis, AtopicEczema, Atopic
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 400
- Registration Number
- NCT06554847
- Locations
- 🇨🇳
Hangzhou First People's Hospital, Hangzhou, Zhejiang, China
🇨🇳Shanghai Dermatology Hospital, Shanghai, Shanghai, China
🇨🇳The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China
Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Target Recruit Count
- 60
- Registration Number
- NCT06533605
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
- Conditions
- Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-10-21
- Target Recruit Count
- 80
- Registration Number
- NCT06522828
- Locations
- 🇨🇳
Chongqing Cancer Hospital, Chongqing, China
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 130
- Registration Number
- NCT06493760
- Locations
- 🇨🇳
Liu Tianshu, Shanghai, Shanghai, China